Back to Results

Kala Pharmaceuticals Inc (KALA)

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for rare and severe eye diseases. Its lead candidate, KPI-012, is being evaluated in a Phase 2b clinical trial for persistent corneal epithelial defects, with additional potential applications in limbal stem cell deficiency and other uncommon corneal disorders. The company is also advancing KPI-014 in preclinical development for rare inherited retinal diseases. Incorporated in 2009 and headquartered in Arlington, Massachusetts, the company was previously known as Kala Pharmaceuticals, Inc. before adopting its current name in August 2023. KALA is listed on the NASDAQ as common stock.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-KALA
$0.61
2.4% Upside
Fair
$75 12,420.9% Upside
Not available
Bargain
Fair
0.0%
November 13, 2026
1.2x
11.585 M
3.601 M
0.0%
100.0%
-94.7
197.2%
Valuation • Fair Value

Kala Pharmaceuticals Inc (NASDAQ-KALA) Fair Value by Valuation Model

Review the available estimates for Kala Pharmaceuticals Inc (NASDAQ-KALA), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.61

Estimated upside of 2.4% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.61

Comparable-company valuation reference.

Analyst Price Target

$75 12,420.9% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 4 available valuation references for Kala Pharmaceuticals Inc (NASDAQ-KALA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Kala Pharmaceuticals Inc (NASDAQ-KALA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-24.069 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Kala Pharmaceuticals Inc (NASDAQ-KALA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Kala Pharmaceuticals Inc (NASDAQ-KALA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

5

Mid-range quality score.

Altman Z-Score

-94.7

Lower score that deserves closer risk review.

FCF / Net Income

197.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Kala Pharmaceuticals Inc (NASDAQ-KALA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Kala Pharmaceuticals Inc (NASDAQ-KALA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

52

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Kala Pharmaceuticals Inc (NASDAQ-KALA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Kala Pharmaceuticals Inc (NASDAQ-KALA) Stock Forecast & Technical Outlook

Review Kala Pharmaceuticals Inc (NASDAQ-KALA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Kala Pharmaceuticals Inc (NASDAQ-KALA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Kala Pharmaceuticals Inc (NASDAQ-KALA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Kala Pharmaceuticals Inc (NASDAQ-KALA) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Kala Pharmaceuticals Inc (NASDAQ-KALA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Kala Pharmaceuticals Inc (NASDAQ-KALA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Kala Pharmaceuticals Inc (NASDAQ-KALA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Kala Pharmaceuticals Inc (NASDAQ-KALA) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Kala Pharmaceuticals Inc (NASDAQ-KALA) Stock FAQ

Data-supported answers about Kala Pharmaceuticals Inc (NASDAQ-KALA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.61
Estimated upside 2.4%
Valuation Rating
Undervalued
Estimated upside of 2.4%
Analyst Target
$75 12,420.9% Upside
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for Kala Pharmaceuticals Inc (NASDAQ-KALA) is $0.61. This implies an estimated upside of 2.4% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 2.4% versus the current market price.

The available analyst price target for Kala Pharmaceuticals Inc (NASDAQ-KALA) is $75 12,420.9% Upside.

The current financial health read for Kala Pharmaceuticals Inc (NASDAQ-KALA) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Kala Pharmaceuticals Inc (NASDAQ-KALA) is November 13, 2026.

The latest available data indicates no current dividend yield for Kala Pharmaceuticals Inc (NASDAQ-KALA).

The current market capitalization listed for Kala Pharmaceuticals Inc is 11.585 M.

The current enterprise value listed for Kala Pharmaceuticals Inc is 3.601 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Kala Pharmaceuticals Inc is NASDAQ-KALA, and the stock is listed on NASDAQ.

Kala Pharmaceuticals Inc (NASDAQ-KALA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Kala Pharmaceuticals Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Kala Pharmaceuticals Inc is 100.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B